Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 326 to 350 of 1159 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
834 increased Increased inflammatory response (HP:0012649) 1868: Hyperinflammation
833 increased tumor necrosis factor secretion (GO:1990774) tumor necrosis factor alpha (PR:000000134) 1868: Hyperinflammation
832 increased interleukin-1 beta production (GO:0032611) interleukin-1 beta (PR:000001136) 1868: Hyperinflammation
831 increased interleukin-6 production (GO:0032635) interleukin-6 (PR:000001393) 1868: Hyperinflammation
830 increased regulation of chronic inflammatory response (GO:0002676) 1868: Hyperinflammation
829 increased Increased inflammatory response (HP:0012649) interleukin-1 beta (PR:000001136) None
828 increased Increased inflammatory response (HP:0012649) tumor necrosis factor alpha (PR:000000134) None
827 increased Increased inflammatory response (HP:0012649) interleukin-6 (PR:000001393) None
826 increased chronic inflammatory response (GO:0002544) 1868: Hyperinflammation
825 abnormal otic vesicle formation (GO:0030916) 1930: altered, inner ear development
824 increased viral release from host cell (GO:0019076) 1939: Viral infection and host-to-host transmission, proliferated
823 increased synaptic transmission, glutamatergic (GO:0035249) L-glutamate(1-) (CHEBI:29985) 1350: Increased, glutamate
822 increased synaptic transmission, glutamatergic (GO:0035249) glutamate(1-) (CHEBI:14321) None
821 increased synaptic transmission, glutamatergic (GO:0035249) None
820 decreased apoptotic process (GO:0006915) ciliated epithelial cell (CL:0000067) 914: Decrease, Apoptosis of ciliated epithelial cells
819 increased phosphorylation (GO:0016310) epidermal growth factor receptor (PR:000006933) 941: Activation, EGFR
818 increased angiotensin-converting enzyme 2 (PR:000003622) 1854: Dysregulation, ACE2 expression and activity
817 decreased protein localization to cell surface (GO:0034394) angiotensin-converting enzyme 2 (PR:000003622) 1854: Dysregulation, ACE2 expression and activity
816 increased carboxypeptidase activity (GO:0004180) angiotensin-converting enzyme 2 (PR:000003622) 1854: Dysregulation, ACE2 expression and activity
815 increased mRNA transcription (GO:0009299) angiotensin-converting enzyme 2 (PR:000003622) 1854: Dysregulation, ACE2 expression and activity
814 decreased angiotensin-converting enzyme 2 (PR:000003622) None
813 increased regulation of peptidase activity (GO:0052547) angiotensin-converting enzyme (human) (PR:P12821) None
812 increased mRNA transcription (GO:0009299) angiotensin-converting enzyme 2 (human) (PR:Q9BYF1) None
811 increased glycosylation (GO:0070085) mucin-5AC (PR:000031343) 1910: Mucus Viscosity, Increased
810 functional change vision trait (VT:0002090) eye (UBERON:0000970) 1643: Altered, Visual function